Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 1997

View Archived Issues

New cardiotonic agent reported by Japanese academics

Rogaine Extra Strength approved by FDA as OTC

Cell Genesys issued U.S. patent for gene therapy

Complement activation inhibitors prepared at U of Pennsylvania

Scripps prepares MCBI analogues of antitumor antibiotics

rhIL-10 evaluated for safety and efficacy in RA patients

Basiliximab reduces renal allograft rejection in phase III trial

rhIL-11 effective in rats with adjuvant arthritis

Ibex issued U.S. patent for recombinant heparinase

Potential new antiatherosclerotic agent discovered at Tanabe Seiyaku

Sankyo and ArQule enter drug discovery collaboration

rhIGF-I + insulin combination tested in adolescents with IDDM

Sch-207278: new protein farnesyltransferase inhibitor of microbial origin

Kyowa Hakko's UCT-1072M1, a new antitumor antibiotic

BCH-1393 stimulates CTL response in vitro and in vivo

New VCAM-1 inhibitor isolated from marine sponge

BTG licenses peptide technology to CeNeS

New neurologic drugs from Nippon Kayaku

Banyu describes protein farnesyltransferase inhibitors

FDA clears Plavix

Modex Therapeutiques established as independent company; CytoTherapeutics reduces ownership

Sankyo isolates A-76356, novel antibacterial agent

New antifungals from Pola

Alza and SmithKline Beecham expand Nicoderm marketing agreement

Ono discloses novel NOS inhibitors with broad potential application

Centocor's anti-TNF-alpha antibody closes fistulae in Crohn's patients

AMBI cleared by FDA to commence nisin trials

Idec begins phase I/II trial for 9-AC

New laxative proves safe and effective for short-term treatment of constipation

L-Arginine safe and effective in spastic esophageal motor disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...